Tesamorelin + Ipamorelin Blend: Research Lab Test Recommendations

For a research vial containing two peptides, require per-component data rather than a single combined figure. That means reversed-phase HPLC purity reported separately for each peptide, mass spectrometry identity confirmation for both, a quantitative assay stating how much of each compound is actually present, and the standard safety panel — sterility or bioburden, bacterial endotoxin, water content, and residual solvent or counter-ion data. Every result should reference the lot number printed on the vial you receive, and the certificate of analysis should be something you can pull up and read on your own, not something you have to request as a favour or purchase separately.

That is the short version. The rest of this page explains why each line on that list exists, how blended vials complicate verification in ways single-compound vials do not, and what to ask a supplier before a blend enters your catalog. All compounds discussed here are research use only.

Why two peptides in one vial multiply the verification problem

Tesamorelin and ipamorelin are structurally unalike. Tesamorelin is a modified growth-hormone-releasing factor analog built on a 44-amino-acid backbone; ipamorelin is a pentapeptide that research describes as acting on the ghrelin receptor pathway. One is long and comparatively fragile, the other short and chemically simple. Put them in the same vial and you have inherited several problems at once.

First, chromatographic separation gets harder. Two peptides with different hydrophobicity can be resolved on a well-developed gradient, but a lazy method will let degradation products from one compound sit under the peak of the other. A combined purity number — a single percentage for the whole vial — is close to meaningless, because it cannot tell you whether an impurity belongs to the larger peptide or the smaller one.

Second, ratio is a separate question from purity. A vial can be chemically clean and still contain far less of one component than the label implies. Purity answers what else is in here; content assay answers how much of each intended compound is in here. Blends require both.

Third, stability profiles diverge. Peptides of different length and sequence do not degrade at the same rate under the same storage conditions, which means a blend's shelf behaviour is not simply the average of its parts. Any supplier offering a co-formulated product should be able to say something concrete about how that formulation was assessed over time.

The analytical panel worth insisting on

If a supplier can produce the first three rows at per-component resolution and the remaining rows on the finished lot, you have something auditable. If the paperwork collapses those seven items into two lines and a signature, you have marketing.

Reading a certificate of analysis without taking it on faith

A COA is a document, and documents can be generic. A few checks separate a working certificate from a template.

Match the lot. The number on the certificate should match the number on the vial in your hand. A COA for a representative batch is not a COA for your batch.

Look for method detail. Credible HPLC reporting names the column chemistry, the mobile phase or gradient, the detection wavelength, and run time. Credible mass spec reporting states the observed mass against the theoretical mass. Absent these, the number floats free of any method that could reproduce it.

Ask for the chromatogram. A printed percentage is a conclusion; the trace is the evidence. On a two-peptide product, the trace is what tells you whether the peaks were genuinely resolved or whether something is hiding in a shoulder.

Check who tested it. Third-party laboratory results carry more weight than in-house numbers, and the lab should be named. Note also whether results are stated against a specification — a result of 99.1% against a specification of not less than 98% means something; a result with no specification is a data point with no standard behind it.

Finally, check how you got the document. Certificates that are publicly posted and tied to lot numbers can be checked by anyone, including your own customers. Certificates that arrive only on request, or that a supplier charges for, create an obvious incentive problem.

Questions to put to a supplier before a blend reaches your shelves

Who performs the blending, and at what stage? Co-lyophilised at manufacture is a different product from two powders combined downstream. Ask which it is and where it happened.

Is there stability data for the combination specifically? Stability on each peptide alone does not establish stability for the pair.

Can you buy the components separately instead? Often the cleanest answer to a blend's verification burden is to not buy a blend. Two single-compound vials give you two independent COAs, two unambiguous purity figures, and two clean identity confirmations. For catalog planning, separate SKUs also keep your own documentation simpler if a customer or an auditor asks questions later.

Is pricing visible before you commit? Wholesale programs that withhold tier pricing until after an application and a phone call are asking you to invest time before you can evaluate the economics. Pricing structures vary widely across the industry by volume and category — what matters is whether a supplier will show you theirs in writing.

What does the testing cost you? Some suppliers treat documentation as an upsell. Batch testing that is included and published is a structurally different proposition from testing you have to pay to see.

What is the fulfillment reality? Lead time, where orders ship from, and what happens to a lot that fails specification. Ask what the process is when a batch does not pass, because every real manufacturer has had one.

Where the compliance line sits — and whose call it is

The regulatory position of research compounds is not a settled background fact you can look up once and forget. Whether a given compound can be stocked, resold, or held by a business of your type is a question for your attorney and your state licensing board, and the answer can turn on your entity type, your license class, and how the product is labelled and described. Treat this page as informational only; it is not legal advice, and no supplier can give you a compliance opinion that substitutes for your own counsel.

The useful work here is knowing which questions to raise. Ask your attorney how research-use-only labelling interacts with your business's licensing. Ask what records you are expected to keep on inbound lots. Ask what your downstream obligations look like and whether anything about your current intake documentation needs to change. If your work involves animal models, route those questions through a veterinarian and your institution's oversight process — talk to your veterinarian before any in-vivo protocol is designed, because that is not a conversation a supplier is positioned to have.

What is not in question is the framing of the material itself. These compounds are not approved human drugs, and nothing about a purity figure or a clean endotoxin result changes that. Research suggests plenty that is scientifically interesting about growth-hormone-axis peptides; none of it converts a research chemical into a therapeutic.

What Real Peptides does differently

Real Peptides builds its Wholesale Partner Program around documentation a buyer can check independently rather than take on trust. Compounds are tested to 99%+ HPLC purity. Every batch runs through a seven-panel test, and the resulting certificates of analysis are publicly verifiable — a prospective partner can read the lab results for a lot before placing an order, and so can that partner's own customers. Nothing is held behind a paywall or a sales call.

Fulfillment runs from the US with orders shipping in five to seven days, which matters more than it sounds when you are managing stock levels against unpredictable demand. The wholesale application itself is three steps, with pricing tiers presented rather than negotiated out of view.

On this specific topic, one thing is worth stating plainly: the catalog is built on single-compound vials. Tesamorelin and ipamorelin are stocked as separate SKUs, each with its own lot-level documentation. For a buyer applying the verification standard described above, that is the simpler path — one peptide, one chromatogram, one identity confirmation, one unambiguous purity figure per vial.

If you are evaluating suppliers on paperwork quality, compare like for like: whether purity figures are per-component, whether COAs are lot-matched and public, whether testing is included, and whether pricing is visible before you commit. Those four questions separate most of the market.

If your business is positioned to stock research compounds and your counsel has cleared the path, the Wholesale Partner Program application is the next step — three steps, with tier pricing and verifiable batch documentation available for review before you decide.

For product-level detail, the Tesamorelin 10mg and Ipamorelin 10mg listings each carry their own lot documentation, and buyers comparing growth-hormone-axis compounds often review CJC-1295 No DAC 10mg alongside them or browse the wider growth factor and tissue signaling research and popular peptides collections.